A Phase 1b, Open-label, Boost-optimization Study of an Adenoviral- Vector Based Oral Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 Administered Orally to Healthy Adult Volunteers
Latest Information Update: 24 May 2024
At a glance
- Drugs VXA G1.1 NN (Primary)
- Indications Norovirus infections
- Focus Pharmacodynamics
- Acronyms VXA-NVV-105
- Sponsors Vaxart
- 24 Feb 2022 According to a Vaxart media release, the Company expects complete data to be available in the first half of 2022.
- 10 Jan 2022 Status changed from active, no longer recruiting to completed.
- 04 Nov 2021 According to the Vaxart media release, the company expects initial data from this study in Q1 2022 and more complete data by Q2 2022.